Cephalon invests $20M in Acusphere

11/5/2008 | American City Business Journals

Cephalon will invest $20 million in Acusphere, gaining an exclusive worldwide license to AI-525 -- an injectable version of celecoxib, an anti-inflammatory drug. The investment also allows Cephalon to license Acusphere's blood-imaging agent Imagify, which is pending FDA approval.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care